ESPR
Price
$2.32
Change
+$0.10 (+4.50%)
Updated
Sep 2 closing price
Capitalization
467.76M
63 days until earnings call
SUPN
Price
$44.91
Change
+$0.37 (+0.83%)
Updated
Sep 3, 11:36 AM (EDT)
Capitalization
2.5B
69 days until earnings call
Interact to see
Advertisement

ESPR vs SUPN

Header iconESPR vs SUPN Comparison
Open Charts ESPR vs SUPNBanner chart's image
Esperion Therapeutics
Price$2.32
Change+$0.10 (+4.50%)
Volume$7.95M
Capitalization467.76M
Supernus Pharmaceuticals
Price$44.91
Change+$0.37 (+0.83%)
Volume$100
Capitalization2.5B
ESPR vs SUPN Comparison Chart in %
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. SUPN commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a Buy and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (ESPR: $2.32 vs. SUPN: $44.54)
Brand notoriety: ESPR and SUPN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ESPR: 157% vs. SUPN: 100%
Market capitalization -- ESPR: $467.76M vs. SUPN: $2.5B
ESPR [@Pharmaceuticals: Generic] is valued at $467.76M. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.5B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.75B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ESPR and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 2 TA indicator(s) are bullish while SUPN’s TA Score has 4 bullish TA indicator(s).

  • ESPR’s TA Score: 2 bullish, 5 bearish.
  • SUPN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SUPN is a better buy in the short-term than ESPR.

Price Growth

ESPR (@Pharmaceuticals: Generic) experienced а +5.94% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +0.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.70%. For the same industry, the average monthly price growth was +13.59%, and the average quarterly price growth was +82.69%.

Reported Earning Dates

ESPR is expected to report earnings on Nov 05, 2025.

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($2.5B) has a higher market cap than ESPR($468M). SUPN YTD gains are higher at: 23.175 vs. ESPR (5.455). SUPN has higher annual earnings (EBITDA): 174M vs. ESPR (-32.5M). SUPN has more cash in the bank: 523M vs. ESPR (86.1M). SUPN has less debt than ESPR: SUPN (31.8M) vs ESPR (302M). SUPN has higher revenues than ESPR: SUPN (665M) vs ESPR (268M).
ESPRSUPNESPR / SUPN
Capitalization468M2.5B19%
EBITDA-32.5M174M-19%
Gain YTD5.45523.17524%
P/E RatioN/A38.73-
Revenue268M665M40%
Total Cash86.1M523M16%
Total Debt302M31.8M950%
FUNDAMENTALS RATINGS
ESPR vs SUPN: Fundamental Ratings
ESPR
SUPN
OUTLOOK RATING
1..100
2419
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
10080
PRICE GROWTH RATING
1..100
3538
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ESPR's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for SUPN (77) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (41) in the Pharmaceuticals Other industry is somewhat better than the same rating for ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than ESPR’s over the last 12 months.

SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as ESPR (100) in the Biotechnology industry. This means that SUPN’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (35) in the Biotechnology industry is in the same range as SUPN (38) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SUPN’s over the last 12 months.

ESPR's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that ESPR’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRSUPN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
N/A
Bullish Trend 6 days ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
62%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 7 days ago
74%
Declines
ODDS (%)
Bearish Trend 23 days ago
90%
Bearish Trend 1 day ago
64%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IMCGX11.18N/A
N/A
Transamerica Mid Cap Growth I
DLBMX17.83N/A
N/A
MassMutual Small Cap Opps A
PGTYX82.51N/A
N/A
Putnam Global Technology Y
UPDDX22.95N/A
N/A
Upright Growth & Income
OLVRX21.77N/A
N/A
JPMorgan Large Cap Value R4

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and DVAX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and DVAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
+4.50%
DVAX - ESPR
32%
Poorly correlated
-2.08%
AQST - ESPR
32%
Poorly correlated
+1.59%
ALKS - ESPR
30%
Poorly correlated
+1.48%
HROW - ESPR
29%
Poorly correlated
-3.28%
AMRX - ESPR
27%
Poorly correlated
+0.21%
More